Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 4 years, most recently at $9.8 million for Q4 2024.

  • Quarterly results put Non-Current Deferred Tax Liability at $9.8 million for Q4 2024, changed 0.49% from a year ago — trailing twelve months through Dec 2024 was $9.8 million (changed 0.49% YoY), and the annual figure for FY2024 was $9.8 million, changed 0.49%.
  • Non-Current Deferred Tax Liability for Q4 2024 was $9.8 million at Crinetics Pharmaceuticals, roughly flat from $9.8 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for CRNX hit a ceiling of $9.8 million in Q4 2023 and a floor of $453000.0 in Q4 2022.
  • Median Non-Current Deferred Tax Liability over the past 3 years was $9.8 million (2024), compared with a mean of $6.7 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: surged 2063.13% in 2023 and later fell 0.49% in 2024.
  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability stood at $453000.0 in 2022, then surged by 2063.13% to $9.8 million in 2023, then decreased by 0.49% to $9.8 million in 2024.
  • The last three reported values for Non-Current Deferred Tax Liability were $9.8 million (Q4 2024), $9.8 million (Q4 2023), and $453000.0 (Q4 2022) per Business Quant data.